Meridian Shares Volatile As FDA Concludes Studies Performed By BD Were Robust & Showed There Was A Significant Chance Of False Results With Magellan's Leadcare Tests; Continues To Recommend That Magellan Lead Tests Not Be Used With Blood Samples From Vein